189 related articles for article (PubMed ID: 21604240)
21. GC-MS analysis of the lipophilic principles of Echinacea purpurea and evaluation of cucumber mosaic cucumovirus infection.
Hudaib M; Fiori J; Bellardi MG; Rubies-Autonell C; Cavrini V
J Pharm Biomed Anal; 2002 Aug; 29(6):1053-60. PubMed ID: 12110390
[TBL] [Abstract][Full Text] [Related]
22. Bioavailability and pharmacokinetic studies of eurycomanone from Eurycoma longifolia.
Low BS; Ng BH; Choy WP; Yuen KH; Chan KL
Planta Med; 2005 Sep; 71(9):803-7. PubMed ID: 16206032
[TBL] [Abstract][Full Text] [Related]
23. Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide content.
Modarai M; Gertsch J; Suter A; Heinrich M; Kortenkamp A
J Pharm Pharmacol; 2007 Apr; 59(4):567-73. PubMed ID: 17430641
[TBL] [Abstract][Full Text] [Related]
24. Macrophage activating effects of new alkamides from the roots of Echinacea species.
Chen Y; Fu T; Tao T; Yang J; Chang Y; Wang M; Kim L; Qu L; Cassady J; Scalzo R; Wang X
J Nat Prod; 2005 May; 68(5):773-6. PubMed ID: 15921428
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Echinacea alkylamide pharmacokinetics between liquid and tablet preparations.
Matthias A; Addison RS; Agnew LL; Bone KM; Watson K; Lehmann RP
Phytomedicine; 2007 Sep; 14(9):587-90. PubMed ID: 17289362
[TBL] [Abstract][Full Text] [Related]
26. Combined extracts of Echinacea angustifolia DC. and Zingiber officinale Roscoe in softgel capsules: Pharmacokinetics and immunomodulatory effects assessed by gene expression profiling.
Dall'Acqua S; Grabnar I; Verardo R; Klaric E; Marchionni L; Luidy-Imada E; Sut S; Agostinis C; Bulla R; Perissutti B; Voinovich D
Phytomedicine; 2019 Dec; 65():153090. PubMed ID: 31557666
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous analysis of alkamides and caffeic acid derivatives for the identification of Echinacea purpurea, Echinacea angustifolia, Echinacea pallida and Parthenium integrifolium roots.
Laasonen M; Wennberg T; Harmia-Pulkkinen T; Vuorela H
Planta Med; 2002 Jun; 68(6):572-4. PubMed ID: 12094312
[TBL] [Abstract][Full Text] [Related]
28. Echinacea alkamides prevent lipopolysaccharide/D-galactosamine-induced acute hepatic injury through JNK pathway-mediated HO-1 expression.
Hou CC; Huang CC; Shyur LF
J Agric Food Chem; 2011 Nov; 59(22):11966-74. PubMed ID: 21985290
[TBL] [Abstract][Full Text] [Related]
29. Comparison of chemical components and antioxidants capacity of different Echinacea species.
Sloley BD; Urichuk LJ; Tywin C; Coutts RT; Pang PK; Shan JJ
J Pharm Pharmacol; 2001 Jun; 53(6):849-57. PubMed ID: 11428661
[TBL] [Abstract][Full Text] [Related]
30. Mast cell degranulation and calcium influx are inhibited by an Echinacea purpurea extract and the alkylamide dodeca-2E,4E-dienoic acid isobutylamide.
Gulledge TV; Collette NM; Mackey E; Johnstone SE; Moazami Y; Todd DA; Moeser AJ; Pierce JG; Cech NB; Laster SM
J Ethnopharmacol; 2018 Feb; 212():166-174. PubMed ID: 29042288
[TBL] [Abstract][Full Text] [Related]
31. Echinacea alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways.
Gertsch J; Schoop R; Kuenzle U; Suter A
FEBS Lett; 2004 Nov; 577(3):563-9. PubMed ID: 15556647
[TBL] [Abstract][Full Text] [Related]
32. High performance liquid chromatography/electrospray ionization mass spectrometry for simultaneous analysis of alkamides and caffeic acid derivatives from Echinacea purpurea extracts.
Cech NB; Eleazer MS; Shoffner LT; Crosswhite MR; Davis AC; Mortenson AM
J Chromatogr A; 2006 Jan; 1103(2):219-28. PubMed ID: 16298376
[TBL] [Abstract][Full Text] [Related]
33. [Pharmaceutical comparability of different therapeutic Echinacea preperations].
Osowski S; Rostock M; Bartsch HH; Massing U
Forsch Komplementarmed Klass Naturheilkd; 2000 Dec; 7(6):294-300. PubMed ID: 11155023
[TBL] [Abstract][Full Text] [Related]
34. A sensitive LC-MS/MS method for the quantitative analysis of the Echinacea purpurea constituent undeca-2-ene-8,10-diynoic acid isobutylamide in human plasma.
Goey AK; Sparidans RW; Meijerman I; Rosing H; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jan; 879(1):41-8. PubMed ID: 21123121
[TBL] [Abstract][Full Text] [Related]
35. Quantification of α- and β-amyrin in rat plasma by gas chromatography-mass spectrometry: application to preclinical pharmacokinetic study.
Ching J; Lin HS; Tan CH; Koh HL
J Mass Spectrom; 2011 May; 46(5):457-64. PubMed ID: 21500304
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic evaluation of visnagin and Ammi visnaga aqueous extract after oral administration in rats.
Haug KG; Weber B; Hochhaus G; Butterweck V
Planta Med; 2012 Nov; 78(17):1831-6. PubMed ID: 23096256
[TBL] [Abstract][Full Text] [Related]
37. Hydroxypropyl-beta-cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat.
Zuo Z; Tam YK; Diakur J; Wiebe LI
J Pharm Pharm Sci; 2002; 5(3):292-8. PubMed ID: 12553899
[TBL] [Abstract][Full Text] [Related]
38. Alkamides from Echinacea inhibit cyclooxygenase-2 activity in human neuroglioma cells.
Hinz B; Woelkart K; Bauer R
Biochem Biophys Res Commun; 2007 Aug; 360(2):441-6. PubMed ID: 17599805
[TBL] [Abstract][Full Text] [Related]
39. The role of alkamides as an active principle of echinacea.
Woelkart K; Bauer R
Planta Med; 2007 Jun; 73(7):615-23. PubMed ID: 17538868
[TBL] [Abstract][Full Text] [Related]
40. Patterns of Variation in Alkamides and Cichoric Acid in Roots and Aboveground Parts of Echinacea purpurea (L.) Moench.
Qu L; Chen Y; Wang X; Scalzo R; Davis JM
HortScience; 2005 Aug; 40(5):1239-1242. PubMed ID: 16429598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
